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Abstract
Objective To evaluate the effectiveness of contemporary mammography
screening using individual information about screening history and breast
cancer mortality from public screening programmes.
Design Prospective cohort study of Norwegian women who were followed
between 1986 and 2009. Within that period (1995-2005), a national
mammography screening programme was gradually implemented, with
biennial invitations sent to women aged 50-69 years.
Participants All Norwegian women aged 50-79 between 1986 and 2009.
Main outcome measures Multiple Poisson regression analysis was
used to estimate breast cancer mortality rate ratios comparing women
who were invited to screening (intention to screen) with women who
were not invited, with a clear distinction between cases of breast cancer
diagnosed before (without potential for screening effect) and after (with
potential for screening effect) the first invitation for screening. We took
competing causes of death into account by censoring women from further
follow-up who died from other causes. Based on the observed mortality
reduction combined with the all cause and breast cancer specific mortality
in Norway in 2009, we used the CISNET (Cancer Intervention and
Surveillance Modeling Network) Stanford simulation model to estimate
how many women would need to be invited to biennial mammography
screening in the age group 50-69 years to prevent one breast cancer
death during their lifetime.
Results During 15 193 034 person years of observation (1986-2009),
deaths from breast cancer occurred in 1175 women with a diagnosis
after being invited to screening and 8996 women who had not been
invited before diagnosis. After adjustment for age, birth cohort, county
of residence, and national trends in deaths from breast cancer, the
mortality rate ratio associated with being invited to mammography
screening was 0.72 (95% confidence interval 0.64 to 0.79). To prevent
one death from breast cancer, 368 (95% confidence interval 266 to 508)
women would need to be invited to screening.
Conclusion Invitation to modern mammography screening may reduce
deaths from breast cancer by about 28%.
Introduction
The efficacy of mammography screening was tested in
randomised trials in the 1970s and 1980s.
1 More than 10 years
ago, an overview by the World Health Organization indicated
thatmammographyscreeningmayreducemortalityfrombreast
cancer by 25%.
2 However, the methods used by some of the
original trials have been criticised, and a report from the
Cochrane Collaboration considered the estimates of mortality
benefit from many of those trials to be invalid.
3 4 Recent
advancesinmodernchemotherapyandadjuvanttreatmenthave
improved the survival of women with breast cancer,
5 6 and
progress in treatment has led some investigators to question the
need for early detection of breast cancer by mammography
screening.
7
Updated studies are clearly needed, but new randomised trials
are not realistic and evaluations of modern screening require
accurate information about screening history compared with
the timing of breast cancer diagnosis, as well as precise and
long term follow-up of mortality. Many observational studies
have assessed breast cancer mortality associated with
mammography screening, but results have been inconsistent,
rangingfromnoeffecttoimprovedmortalitybenefitsthanthose
obtained in the original screening trials.
8-16 Norway provides an
idealsettingtostudytheeffectsofmammographyscreening,
17 18
but in two previous Norwegian studies that used an incidence
based mortality approach, only fractions of the available and
potentially important data were included in the analyses.
8 11
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Research
RESEARCHWe analysed data from all women in Norway who were aged
50 to 79 during 1986 to 2009, the period during which the
Norwegianmammographyscreeningprogrammewasgradually
implemented (1995-2005). We compared the rates of deaths
from breast cancer among those who were invited to screening
(with a potential for screening effect) with those who had not
been invited to screening before breast cancer was diagnosed
(without a potential screening effect).
Methods
The Norwegian breast cancer screening
programme
TheNorwegianbreastcancerscreeningprogrammewasinitiated
by the Norwegian government in 1995 and introduced in four
counties in November of that year. The programme was
gradually implemented in the remaining 15 counties, with
complete national coverage achieved in 2005. The screening
programmeisadministeredbytheNorwegianCancerRegistry,
and all women aged 50-69 are invited to screening every two
years. Two view screening mammograms are taken in breast
diagnostic centres exclusively dedicated to the diagnosis and
treatmentofbreastdiseases.Tworeadersindependentlyevaluate
the mammograms, and women whose mammograms require
furtherconsiderationarereferredfordiagnosticmammography,
and, if necessary, for additional clinical evaluation. Attendance
for screening has been relatively stable, at approximately 76%.
The reporting of cancer to the Norwegian cancer registry is
mandatory, and diagnostic information is obtained separately
from clinicians, pathologists, and death certificates, with 0.2%
of all cancers ascertained only from death certificates.
18 The
unique 11 digit personal identification number of each citizen
allowsfollow-upforcausespecificmortality,whichisprovided
by Statistics Norway. We used data used on individual dates of
screeninginvitations,datesofbreastcancerdiagnoses,anddates
of breast cancer deaths.
Study participants
WeincludedallNorwegianwomenaged50to79yearsbetween
1986and2009.Thedynamicnatureofinclusionsandexclusions
tothecohortbyagemeansthatwomencontributedpersonyears
of observation from the age when they were eligible to be
observed until they were censored from further observation,
either because of death (from breast cancer or other causes),
they had reached 80 years of age, or they had reached the end
of follow-up (31 December 2009). The actual number of
participatingwomenindynamiccohortswillvaryforeachgiven
year, but in 2000 a total of 638 238 women were under
observation, and the study included 15 193 034 person years of
observation.
ThefirstinvitationtotakepartintheNorwegianmammography
screening programme depended on the woman’s county of
residenceandherbirthcohort,butfrom1995to2005allwomen
in the country aged between 50 and 69 were gradually invited
to participate. The supplementary figure shows the mortality
rate of breast cancer in Norway (1986-2009) among women
aged 50-79 and the period during which the mammography
screeningprogrammewasimplementedinNorwegiancounties
(1995-2005).
Statistical analysis
In the analysis, we regarded women with a diagnosis of breast
cancer after the invitation date to mammography screening as
being exposed to screening, and women with a diagnosis of
breast cancer before the invitation date as being unexposed to
screening. To assess the effect of invitation to screening we
comparedincidencebasedbreastcancermortalityamongwomen
invited to screening (intention to screen) with those not invited,
under the counterfactual assumption that if invited women had
not been invited, their risk of death from breast cancer would
be similar to that of women who had not (yet) been invited.
Toaccountfordifferencesinageandeffectsofbirthcohortand
calendartime,weusedamultivariablePoissonregressionmodel.
To achieve optimal flexibility in the statistical adjustments, we
used natural splines to allow for non-linear variations in age,
period, and cohort effects (see R code in supplementary
appendixd).Insensitivityanalyses,wealsotestedthestatistical
models without smoothing of period and cohort effects, and we
used age and period models without the birth cohort variable
to limit the potential for colinearity. In addition because the
rates for breast cancer mortality differed slightly between
counties, we adjusted for county of residence. In the Poisson
regression analysis we took competing causes of death into
accountbycensoringfromfurtherfollow-upthosewomenwho
died from causes other than breast cancer.
The time interval from diagnosis until death from breast cancer
varies from a few months to many years, and therefore we
carefully separated breast cancers diagnosed in women before
invitationtofirstscreeningfromthosediagnosedafterinvitation
to first screening to avoid misclassification of breast cancer
deathsaccordingtoexposurestatus(invitedornotinvitedbefore
diagnosis). At the beginning of the implementation period in
eachcountyalmostalldeathsfrombreastcanceroccurredamong
women with a diagnosis before screening invitations started.
Overtimeagraduallyhigherproportionofbreastcancerdeaths
could be attributed to breast cancers diagnosed after women
had been invited to screening. We accounted for this dynamic
change by estimating the proportion of the observed breast
cancer mortality that was expected to be due to cancers
diagnosed after the first screening invitation, assuming that
invitationstoscreeninghadnoeffectonbreastcancermortality.
Intheestimationweusedtheintervalfromdiagnosisuntildeath
from breast cancer among women (in 10 year age groups) who
had not yet been invited. Thus we avoided the lead time bias
that would have occurred if we had used the interval from
diagnosis until breast cancer death among invited women. As
an offset in the statistical modelling we added to the model the
estimated proportion of breast cancer deaths that was attributed
to breast cancers diagnosed after screening invitation, thus
adjusting the expected breast cancer mortality for each group
according to invitation status (see supplementary appendix for
formulas and implementation).
The individual data were precisely split according to exposure
status, with separation of invited and not yet invited women
within each age-period-county combination during the
implementation period of mammography screening in each
county. Thus the analysis compares two groups, using detailed
information, with adjustment for differences by age, period,
cohort,andcounty.Usingthisdynamicmodellingapproachwe
could utilise all the available individual data in the analysis,
without the limitation of selected comparison groups, as in
previous studies using data from Norway.
8 11
To account for all random statistical uncertainty, we used
bootstrap replications and calculated 95% confidence intervals
for the estimated effects associated with invitation to
mammography screening. To test the robustness of the results,
we repeated the analyses under a broad range of statistical
assumptions, including a pure age-period-county model,
different smoothing of age and period effects, different choice
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RESEARCHof reference period and reference age groups, and varying the
effect of screening invitation by calendar year.
Since screening effects are likely to vary by age and time since
screening, these variables may not be balanced between
comparison groups. In a separate sensitivity analysis we
thereforeweightedthescreeningvariablebasedonthesimulated
screening effects by age and time since screening provided by
the CISNET (Cancer Intervention and Surveillance Modeling
Network) Stanford simulation model.
19-21
Wealsocalculatedthenumberofwomenwhoneedtobeinvited
to screening to prevent one death from breast cancer. The
number relates to Norwegian women in the age group 50-69
years in 2009. Firstly, we assumed an effect of screening
invitations corresponding to the reduction in breast cancer
mortality that we observed in our data. Secondly, we used the
observedbreastcancermortalityinNorwayin2009andadjusted
fortheobservedreductioninmortalityassociatedwithinvitation
to mammography screening. Thus we could estimate the likely
breastcancermortalityintheabsenceofscreening.Thirdly,we
used the observed all cause mortality in Norway in 2009 and
calculated the probability that women who were first invited at
50 years of age were alive at a given age (51, 52, 53, and so on
up to 79 years of age). Effects of screening are likely to vary
byageandbytimesincescreening,buttheseeffectsaredifficult
to estimate empirically owing to a limited number of
observations.ThereforeweappliedtheCISNETStanfordmodel
scaled to the observed Norwegian breast cancer mortality
reduction to estimate the likely screening effects by age and
time since screening. In the CISNET Stanford model, smaller
tumour size and lower clinical stage at diagnosis resulting from
an earlier diagnosis is assumed to explain potential reductions
in breast cancer mortality. By combining the breast cancer
mortality rates in Norway in 2009, the estimated reduction in
breast cancer mortality, and the CISNET Stanford simulation
model, we calculated the absolute reduction in breast cancer
mortality that could be attributed to screening within each age
group.Aftercombiningtheestimatedreductioninbreastcancer
mortality with the probability of reaching a certain age, given
the observed all cause mortality in 2009, we could summarise
the data and estimate the probability that one death from breast
cancer could be avoided by being invited to mammography
screening. Thus the inverse of that probability yielded the
number of women aged 50-69 who need to be invited to
screening to prevent one death from breast cancer during their
lifetime. (See the spreadsheet in the supplementary appendix
for further details.)
All statistical analyses were conducted using the R statistical
package
22 (see the supplementary appendix for details of the
calculation).
Results
During 15 193 034 person years of observation, breast cancer
deathsoccurredin1175ofthewomeninvitedtomammography
screeningandin8996ofthewomenwhowerenotinvited.After
adjustment for age, birth cohort, county of residence, and
underlying national trends in breast cancer mortality, the
mortality rate ratio associated with being invited to screening
was 0.72 (95% confidence interval 0.64 to 0.79), indicating a
28%lowerriskofdeathfrombreastcancerinwomenwhowere
invited for screening compared with women who were not
invited (table 1⇓).
Aftertheinvitationstoscreeninghadended(at70yearsofage),
we found that the benefit for breast cancer mortality persisted
(table 2⇓), but with a possible gradual decline by time since
screening (P for trend 0.35). Thus, between five and 10 years
after the invitations to screening had ended, the adjusted
mortality rate ratio was 0.79 (95% confidence interval 0.57 to
1.01).
To test the robustness of the findings we repeated the analyses
under different statistical assumptions (sensitivity analyses),
including leaving out the cohort effect, using non-smoothed
period effects, and weighting the screening effect by age and
time since screening (table 3⇓). However, these additional
procedures did not substantially influence the estimated effect
and yielded mortality rate ratios ranging from 0.71 to 0.75. By
introducing a period dependent screening effect, the results
suggested a possible increasing reduction in breast cancer
mortality by calendar year, but that analysis had limited
statistical power (P=0.29).
We also estimated how many women between 50 and 69 years
of age would need to be invited to mammography screening to
prevent one death from breast cancer, based on the estimated
effectonbreastcancermortalitythatwefoundinthisstudyand
the observed all cause and breast cancer specific mortality in
Norway in 2009. Overall, 368 (95% confidence interval 266 to
508) women in the age group 50-69 years would need to be
invited to biennial mammography screening to prevent one
deathfrombreastcancerduringtheirlifetime(seesupplementary
appendix table for calculation).
Based on the estimated effect of screening invitations (table 1),
wealsoestimatedtheeffectofmammographyscreeningamong
women who actually attended (approximately 76% of invited
women). Thus attendance may be associated with a 37%
reduction in breast cancer mortality (0.28/0.76=0.37), and 280
women would need to attend screening to prevent one death
from breast cancer (368×0.76=280).
Discussion
In this study, based on more than 15 million person years of
observation, we estimated that invitation to mammography
screeningwasassociatedwitha28%reducedriskofdeathfrom
breastcancercomparedwithnotbeinginvitedtoscreening,and
that 368 women need to be invited to screening to prevent one
death from breast cancer. The screening effect persisted but
seemed to be gradually reduced after invitations to screening
hadended.Thelargepopulationandlongfollow-upofmortality
provided precise estimates and suggests that chance is unlikely
to explain the main findings of the study.
Strengths and limitations of this study
Moderntreatmenthasreducedthenumberofdeathsfrombreast
cancer,
5 6 20 and in the analysis we took into account the effect
of changes in nationwide treatment by adjusting for trends in
national breast cancer mortality. To improve and standardise
breastcancertreatmentacrossNorway,clinicalguidelineswere
implemented before mammography screening became
established.Althoughsomedifferencesintreatmentmayremain,
such differences are unlikely to be systematically related to
mammography screening status (invited or not invited).
However, breast diagnostic centres were established in parallel
with the Norwegian mammography screening programme and
resulted in centralisation of care for women with breast cancer.
We cannot exclude the possibility that organisational aspects
of care related to these centres may have contributed to some
ofthedecreaseinbreastcancermortalitythatweobservedafter
invitations to screening.
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RESEARCHBefore the national screening programme, mammography
screening was available at private radiology institutions, and
many women had mammograms for clinical or screening
purposes.
23Assumingthatscreeningactivitywashighlyfrequent,
an increase in breast cancer incidence and some increase in
ductal carcinoma in situ would be expected to precede the
implementation of the screening programme. However, in
contrast with this expectation, no clear increase in incidence
was observed before the national mammography screening
programmewasestablished.
24 25Thereforeitseemsunlikelythat
screening activity before the national programme could have
substantiallyinfluencedandattenuatedtheresultsofthepresent
study.
Comparison with other studies
In some studies, women who attended for mammography
screening were compared with women who did not attend. In
a review of studies that compared breast cancer mortality in
women who did and did not attend for screening programmes
in Europe, attendance was estimated to be associated with a
breast cancer mortality benefit of 31%.
12 In a recent Norwegian
study, attendance was associated with a mortality benefit of
43%.
26 Attendance does, however, imply an active choice, and
womenwhochoosetoattendmaydifferfromthosewhochoose
not to attend in ways that may lead to biased estimates of the
screening effect.
27 To prevent such a bias we analysed the data
according to whether women were invited or not invited to
screening (intention to screen).
TwopreviousprospectivestudiesinNorwayalsousedincidence
basedmortalitytoassessthepotentialbenefitsofmammography
screening.
8 11 In contrast with the present study, those studies
restricted the analyses to selected comparison groups (birth
cohorts or counties) and reported moderate mortality benefits
(10% and 11%, respectively) with low precision (wide
confidence intervals). In the study by Kalager and colleagues,
8
the low precision was due to a short follow-up of mortality,
which ended in 2005. Another limitation was that instead of
using detailed information about the actual age of the women
anddateofscreeninginvitationsineachcounty,theinvestigators
used broad categories that probably resulted in some
misclassification of exposure (screening or not, in relation to
diagnosis).Also,theinvestigatorsincludedbreastcancerdeaths
based on time of diagnosis and not on the actual time of death.
Therefore, women with an earlier diagnosis as a result of
screening were more likely to be included as invited cases
(deaths) than were unscreened women, whose diagnosis was
not forwarded by the screening facility. As a consequence, the
association of screening invitation with breast cancer mortality
is likely to be diluted in that study. In a separate analysis, we
limited our data to more closely match that of Kalager and
colleagues’,
8 and found a reduction in breast cancer mortality
of 14% associated with an invitation to screening, which is
slightly stronger than the effect reported by the investigators
using even fewer detailed data. In the study by Olsen and
colleagues,
11 effects of mammography screening were only
assessed for selected birth cohorts and only in the four counties
wherethescreeningprogrammewasfirstintroduced.Therefore
the investigators missed any effect in the remaining birth
cohorts, as well as in the other 15 Norwegian counties.
In a recent comprehensive review of European studies,
13 two
(fromDenmarkandFinland)thatusedincidencebasedmortality
were identified as particularly reliable.
9 28 According to those
studies,themammographyscreeningprogrammeinCopenhagen
wasassociatedwitha25%reductioninbreastcancermortality,
8
andinFinland,areductionof24%wasattributedtotherecently
established mammography screening programme. The Finnish
study, however, was associated with substantial statistical
uncertainty.
28
It has been questioned whether the evidence from the original
screening trials is still relevant within the context of modern
treatment for breast cancer,
5 6 and with generally greater
awareness of the disease among women. Our findings, as well
as the results from the Danish and Finnish studies,
9 28 suggest
that the relative effectiveness of mammography screening is
comparable to the efficacy reported from some of the
randomised screening trials.
2 29
In our study the estimated benefit for breast cancer mortality
(28%) associated with invitation to mammography screening
indicates a substantial effect, but evolving improvements in
treatment will probably lead to a gradual reduction in the
absolute benefit of screening.
5 20 30 Based on breast cancer
mortality data from 1980, the Euroscreen Working Group
estimated that 111 to 143 women would need to be screened to
prevent one death from breast cancer.
31 Using breast cancer
mortality data from 2009, we estimated that 368 women in the
age group 50-69 years would need to be invited to screening to
prevent one death from breast cancer during their lifetime. Our
higher number is partly attributable to different assumptions
about the duration of the effect of screening and partly
attributable to lower breast cancer mortality in the absence of
screening.Theseculardeclineinbreastcancermortalitycaused
by progress in treatment is substantial, and one consequence of
further improvements in treatment is that increasingly more
women will need to be invited to mammography screening to
prevent one death from breast cancer.
Instead of using individual screening information (incidence
based analysis), other researchers have related the timing of
introducing mammography screening to time trends in breast
cancer mortality.
10 12 In these studies, breast cancers that were
diagnosed before screening cannot be reliably distinguished
from screening detected cancers. In a separate analysis of our
data, we disregarded individual information about the time of
diagnosis, and similar to studies using mortality trend analysis,
we also found no association of the time that mammography
screening was implemented with breast cancer mortality (data
not shown). This illustrates how important it is to properly
separate breast cancers according to screening status at
diagnosis, otherwise any effect of screening will be diluted and
cannot be attributed to screening.
32 Therefore, incidence based
mortality and detailed screening status are necessary
requirementsforanappropriateassessmentoftheeffectiveness
of mammography screening.
32
To avoid bias by subjective modelling, we developed a detailed analysis
protocol and submitted it to the Norwegian Research Council before
data delivery from the Norwegian Cancer Registry. This study is based
on data from the Cancer Registry of Norway. The interpretation and
reporting of these data are the sole responsibility of the authors, and
no endorsement by the Cancer Registry of Norway is intended nor
should be inferred. We thank Sylvia Plevritis and Diego Munoz for
providing inputs needed to derive the number of woman needed to
screen to avoid one breast cancer death; these inputs were taken from
the Stanford breast cancer screening model, funded by the National
Cancer Institute CISNET programme U01CA159256, and were
generated for this study.
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RESEARCHWhat is already known on this topic
Randomised trials from the 1970s and 80s suggested that mammography screening prevents deaths from breast cancer
The methods used by some of the original studies have been criticised, and this has raised doubts about the validity of the findings
New trials on screening are unrealistic, and updated observational studies are needed to reliably compare the effects on breast cancer
mortality among screened and unscreened women
What this study adds
Women invited to screening in the Norwegian mammography screening programme were at a 28% lower risk of death from breast
cancer than women who had not (yet) been invited
Attendance was associated with a 37% lower risk
368 women aged 50-69 would need to be invited to biennial mammography screening to prevent one death from breast cancer during
their lifetime
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RESEARCHTables
Table 1| Mortality rate ratio of breast cancer among women aged 50-79 who were invited or not invited (reference) to the Norwegian
mammography screening programme, 1986-2009
Adjusted† mortality rate
ratio (95% CI)
Age adjusted rate
ratio*
Unadjusted rate
ratio* Rate* (per 100 000) Person years*
Deaths from breast
cancer
Screening status
1.0 (reference) 1.0 (reference) 1.0 (reference) 70.4 12 785 325 8996 Not invited
0.72 (0.64 to 0.79) 0.71 0.69 48.8 2 407 709 1175 Invited
*Using incidence based mortality with separation of breast cancer cases (and corresponding person years at risk) diagnosed before and after invitation to the
screening programme.
†Adjusted for age, birth cohort, national breast cancer mortality trends, and county of residence.
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RESEARCHTable 2| Breast cancer mortality rate ratios associated with invitations to mammography screening programme in relation to screening
period
Mortality rate ratio (95% CI) Screening period
0.70 (0.62 to 0.78) During active (biennial) screening period of programme (age 50-69)
0.77 (0.64 to 0.89) During first five years after invitations to screening ended
0.79 (0.57 to 1.01) 5-10 years after invitations to screening ended
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RESEARCHTable 3| Breast cancer mortality rate ratios associated with invitations to mammography screening programme in alternative (sensitivity)
analyses under different statistical assumptions
Mortality rate ratio (95% CI) Statistical assumptions
0.72 (0.64 to 0.79) Main estimate (from table 1)
Alternative analyses:
0.72 (0.65 to 0. 80) Screening effect weighted by time since first or last screening*
0.75 (0.67 to 0.82) Model without birth cohort effects
0.72 (0.64 to 0.79) Model without smoothing of period effects
0.75 (0.67 to 0.80) Including broader groups (age 40-89 during 1961-2009), screening effect weighted by time
since first or last screening,* and applying incidence based mortality based on pre-screening
data
*According to Cancer Intervention and Surveillance Modeling Network Stanford model, and scaled equal to a constant screening effect between 50 and 74 years
of age.
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